"rocky, in several of your posts you allude to the need for institutional holdings. Can you please tell me why this important and what it will take to entice these groups"
Joan, this in a nutshell, of what it can mean. Money mangers of mutual funds, pensions etc; are looking for growth stocks. They don't buy huge amounts of shares and trade daily or even monthly, they buy and hold until something significant tells them different. With that scenario in place the shares bought and held in essence take those large amount of shares out of the float, meaning they don't trade them..buy and hold. To explain further, I have taken the companies ACT considers competitors and posted their OS#'s and the percentage of the OS# that is owned by Institutions.(see below) The average OS# for those 8 companies is 210MM and average Inst. ownership is 41%. ACT has approx. 1.2 Billion OS# and currently have 138,000 shares under inst. ownership, not really worth a mention..Now that we finished 2010, we may see more reporting of holders for ACT but in all honesty I don't see it changing substantially. We are still considered a speculative penny company which prohibits many money manager from investing although some do. As I have stated prior, imo only, we are at a point in time with clinical trial and possibly more trials as well as Europe infiltration and given the fact our share situation is creeping within striking distance of authorized, I feel it is time, if possible to move to a big board exchange. If nothing else I hope they are at least prescreening with differnt exchanges to see what can be done. All of this is contingent on what management and the new CEO envision ACT as. Will they be satisfied with a buyout? Do they want to be a player as ACTC and if so to what extent? If they desire to be a player for many years in the future then I would capitalize on an exchange move asap and watch what happens with positive results, inst. would no doubt make the move too. I honestly do not believe we will garner true market value with the shares we have now or asking for more. Get this stock in line with competitor OS#'s and Inst. ownership and go about your business. Hire a CFO, have shareholder meetings and big board corporate governance. I feel it is the right time to make a move and more importantly, warranted. As noted, this is my opinion and I hope I answered the importance of Inst. Ownership...thanks joan
(ACT competitors per Prospectus) "In the general area of cell-based therapies (including both ES cell and autologous cell therapies), we compete with a variety of companies, most of whom are specialty biotechnology companies, such as Geron Corporation, Genzyme Corporation, StemCells, Inc., Aastrom Biosciences, Inc., Viacell, Inc., MG Biotherapeutics, Celgene, BioHeart, Inc., Baxter Healthcare, Osiris Therapeutics and Cytori."
Geron Corporation: OS#... 120MM Inst. Ownership...21.2%...25MM shares held
Genzyme Corporation OS#...259MM Inst. Ownership...86%...224MM shares held
StemCells: OS#...127MM Inst..Ownership..15.5%...19.7MM shares held
Aastrom Biosciences: OS#...39MM INST. Ownership..9%... 3.55MM shares held
Celgene Corporation: OS#...471MM Inst. Ownership...83%...390MM shares held
Baxter: OS#...583MM Inst. Ownership..81%...472MM shares held
Osiris Therapeutics : OS#...33MM Inst. Ownership...12%...3.9MM shares held
Cytori: OS#...51MM Inst. Ownership...19%...9.8MM shares held
Institutions are mutual funds, pension plans, trust funds, and other large investors, and account for roughly 50 percent of all stockholdings. The presence of strong institutional sponsorship (large holdings) verifies that a stock is a viable growth candidate.
institutional money managers are more wired into the market than individual investors can ever hope to be. High institutional sponsorship (ownership) means these tuned-in investors have analyzed the company and liked what they saw. Conversely, low institutional ownership means that institutions have analyzed the company and passed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.